Los esteroides anabolizantes androgénicos, riesgos y consecuencias
Anabolic androgenic steroids, risks and consequences
Barra lateral del artículo
PDF
FLIP
HTML
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Contenido principal del artículo
Resumen
El dopaje ha causado mucho daño en el mundo del deporte y de la actividad física, rechazado por deportistas, por entrenadores y por directivos, siendo perseguido, con el fin de ser erradicado de las justas deportivas, donde su empleo es causado por la presión de innumerables factores, que se presentan en el alto rendimiento; sin embargo, se desconoce el impacto y la popularidad que muchas de estas sustancias tienen en la gente del común; quienes buscan una perfección física, desconociendo las alteraciones funcionales, fisiológicas, bioquímicas y psicológicas que, en la mayoría de los casos, son irreversibles, con el único objetivo de encajar en los patrones de belleza, que impone la sociedad. Este trabajo recopila evidencia científica sobre los efectos de la ingesta de esteroides anabólicos androgénicos en el organismo, para generar conciencia en los potenciales usuarios y crear políticas de prevención, frente al consumo indiscriminado de dichas sustancias.
Palabras clave:
Descargas
Detalles del artículo
Referencias (VER)
ALEN, M.; RAKKILA, P.; REINILA, M.; VIHKO, R. 1987. Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. Am. J. Sport Med. 15:357-361.
ALEN, M.; RAKKILA, P.; MARNLEML, J. 1985a. Serum lipide in power athletes self-administering testosterone and anabolic steroids. Int. J. Sport Med. 6(1):139-144.
ALEN, M.; REINILA, M.; VIHKO, R. 1985b. Response of serum hormones to androgen administration in power athletes. Med. Sci. Sports Exerc. 17(3):354- 359.
AMERICAN COLLEGE OF SPORT MEDICINE AMA. 1984. Position stand on the use of Anabolic Androgenic Steroids in Sport. Sport Medicine Bull. 19:13-18.
BHASIN, S.; STORER, T.W.; BERMAN, N.; CALLEGARI, C.; CLEVENGER, B.; PHILLIPS, J.; BUNNELL, T.J.; TRICKER, R.; SHIRAZI, A.; CASABURI, R. 1996. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 335(1):1-7.
BLUE, J.G.; LOMBARDO, J.A. 1999. Steroids and steroid-like compounds. Clin. Sports Med. 18:667- 689.
CATLIN, D.H.; KAMMERER, R.C.; HATTON, C.K.; SEKERA, M.H.; MERDINK, J.M. 1987. Analytical chemistry at the games of the XXIII rd Olympiade in Los Angeles. Clin. Chem. 33:319-327.
CHOI, P.Y.; PARROTT, A.C.; COWAN, D. 1990. High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Hum Psychopharmacol. 5(4):349-356.
CLARK, A.S.; HENDERSON, L.P. 2003. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci. Biobehav. Review. 27(5):413-436.
CONSTITUCIÓN POLÍTICA DE COLOMBIA, Ley 845 del 2003, Diario Oficial 45.348, 21 de octubre del 2003.
DAWES, J.; MANKIN, T. 2004. Muscle dysmorphia. J. Strength Condit. Res. 26:24-25.
DEMLING, R.H. 2005. The role of anabolic hormones for wound healing in catabolic states. J. Burn Wounds. 4:e2.
DOTSON, J.L.; BROWN, R.T. 2007. The history of the development of anabolic-androgenic steroids. Pediatr. Clin. N. Am. 54(4): 761-769.
DUPUIS, D.; ROUGIER, A.; ROGUET, R.; LOTTE, C.; KALOPISSIS, G. 1984. In vivo relationship between horny layer reservoir effect and percutaneous absorption in human and rat. J. Invest. Dermatol. 82:353-356.
EMBLENTON, P.H.; THORNE, G. 2004. Anabolic Primer. Ed. Olympus Sport Nutricion. Barcelona. 45p.
FALDUTO, M.T. 1989. Adverse effects of anabolic steroids. Med. Toxicol. Adverse Drug Exp. 4:254- 271.
FERREIRA, I.M.; VERRESCHI, I,T.; NERY, L.E.; GOLDSTEIN, R.S.; NOE ZAMEL, N.; DINA BROOKS, D.; JARDIM, J.R. 1998. The influence of 6 months of oral AAS on body mass and respiratory muscles in undernourished COPD patients. Chest. 114:19-28.
FREED, D.L.; BANKS, A.J.; LONGSON, D.; BURLEY, D.M. 1975. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. BMJ. 2:471-473.
FUJIOKA, M.; SHINOHARA, Y.; BABA, S.; IRIE, M.; INONUE, K. 1987. Acute suppression of endogenous testosterone levels by exogenous testosterone in normal men. Life Sci. 41:945-949.
GARCÍA MALDONADO, G. 2002. Complicación psiquiátricas por el uso de esteroides anabólicos. Rev. Med. IMSS. 40(2):103-112.
GILL, G.V. 1998. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad. Med. J. 74:45-46.
GLAZER, G. 1991. Arthrogenic effects of anabolic steroids on serum lipid levels. Arch. Intern. Med. 151:1925-1933.
GOLD, J.; BATTERHAM, M.J.; REKERS, H.; HARMS, M.K.; GEURTS, T.B.; HELMYR, P.M.; SILVA DE MENDONÇA, J.; FALLEIROS CARVALHO, L.H.; PANOS, G.; PINCHERA, A.; AIUTI, F.; LEE, C.; HORBAN, A.; GATELL, J.; PHANUPHAK, P.; PRASITHSIRIKUL, W.; GAZZARD, B.; BLOCH, M.; DANNER, S.A. 2006. Effects of nandrolone deeanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med. 7(3):146-155.
GONZÁLEZ ARAMENDI, J.M. 2008. Uso y abuso de esteroides anabolizantes. BIBLID. 26:185-197.
GRACIA-MARCO, L.; REY LÓPEZ, J.P.; CASAJÚS MALLÉN, J.A. 2009. El dopaje en los Juegos Olímpicos de verano (1968-2008). Apuntes Med. Sports. 44:66-73.
HALL, R.C.; CHAPMAN, M.G. 2005. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 46(4):285-290.
HALL, R.C.W.; HALL, R.C.W. 2005. Abuse of Supraphysiologic Doses of Anabolic Steroids. Southern Med. J. 98(5):550-555.
HALLAGAN, J.B.; HALLAGAN, L.F.; SUYAER, M.B. 1989. Anabolic-androgenic steroid use by athletes?. N. Eng. J. Med. 321(15):1042-1045.
HAUPT, H.A.; ROVERE, G.D. 1984. Anabolic steroids: a review of the literature. Am. J. Sports Med. 12:469- 484.
HENGGE, U.R.; BAUMANN, M.; MALEBA, R.; BROCKMEYER, N.H.; GOOS, M. 1996. Oxymetholone promotes weight gain in patients with advanced human inmunodeficiency virus (HIV-1) infection. Br. J. Nutr. 75:129-138.
HERNÁNDEZ, R.; FERNÁNDEZ, C.; BAPTISTA, P. 2006. Metodología de la investigación. Ed. Mc. Graw Hill. México. 216p.
HERNÁNDEZ, R.; FERNÁNDEZ, C.; BAPTISTA, P. 2007. Fundamentos de metodología de la investigación. Ed. Mc. Graw Hill. México. 59p.
HICKSON, R.C.; BALL, K.L.; FALDUTO, M.T. 1989. Adverse effects of anabolic steroids. Med. Toxicol. Adverse Drug Exp. 4:254-271.
HILDEBRAND, R.L. 2007. El programa mundial antidopaje y el médico de atención primaria. Pediatr. Clin. N. Am. 54:701-711.
HOLMA, P.K. 1977. Effects of an anabolic steroid (metandienone) on spermatogenesis. Contraception. 15:151-162.
JAROW, J.P.; LIPSHULTZ, L.I. 1990. Anabolic steroidinduced hypogonadotropic hypogonadism. Am. J. Sports Med. 18:429-431.
JOHANSEN, K.L.; MULLIGAN, K.; SCHAMBELAN, M. 1999. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 281:1275-1281.
JOHANSEN, K.L.; PAINTER, P.L.; SAKKAS, G.K.; GORDON, P.; DOYLE, J.; SHUBERT, T. 2006. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J. Am. Soc. Nephrol. 17:2307-2314.
KAYSER, B.; SMITH, A. 2008. Globalisation of antidoping: the reverse side of the medal. BMJ.337:a584.
KICMAN, A.T.; GOWER, D.B. 2003. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann. Clin. Biochem. 40:321-356.
KOENIG, H.; GOLDSTONE, A.; LU, C.Y. 1982. Testosterone-mediated sexual dimorphism of the rodent heart: ventricular lysosomes, mitochondria, and cell growth are modulated by androgens. Circulation Res. 50:782-787.
KOURI, E.M.; LUKAS, S.E.; POPE, H.G. Jr.; OLIVA, P.S. 1995. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend. 40(1):73-79.
KROCHMAL, L.; WANG, J.C.T.; PATEL, B.; RODGERS, J. 1989. Topical corticosteroid compounding. Effects on physicochemical stability and skin penetration rate. J. Am. Acad. Dermatol. 21:979-984.
KUHN, C.; SWARTZWELDER, S.; WIÑSON, W. 2003. Anabolizantes, estimulantes y calmantes en la práctica deportiva, Barcelona, Ed. Paidotribo. 77p.
KUTSCHER, E.; LUND, B.; PERRY, P. 2002. Anabolic steroids a review for the clinician. Sports Med. 32(5):285-296.
LASARRE, C.; GIRARD, F.; DURN, J.; RAYNAUD, J. 1974. Kinetics of human growth hormone during submaximal exercise. J. Appl. Physiol. 37(6): 826- 830.
LIU, P.Y.; DEATH, A.K.; HANDELSMAN, D.J. 2003. Androgens and cardiovascular disease. Endocr. Rev. 24:313-340.
MacINDOE, J.H.; PERRY, P.J.; YATES, W.R.; HOLMAN, T.L.; ELLINGROD, V.L.; SCOTT, S.D. 1997. Testosterone suppression of the HPT axis. J. Invest. Med. 45: 441-447.
MATHUR, R.S. 1981. Plasma androgens and sex hormone binding globulin (SHBG) in the evaluation of hirsute females. Fert. Ster. 35:29-35.
MATSUMOTO, A.M. 1990. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dosedependent suppression of luteinizing hormone, follicle stimulating hormone, and sperm production. J. Clin. Endocr. Metab. 70:282-287.
MELNIK, B.; JANSEN, T.; GRABBE S. 2007. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J. Dtsch Dermatol. Ges. 5(2):110-117.
MOSS, H.B.; PANZAK, G.L.; TARTER, R.E. 1992. Personality, mood and psychiatric symptoms among anabolic steroid users. Am. J. Addict. 1(4):315-324.
OLSSON, A. 1974. Effects of oxandrolone on plasma lipoproteins and the intraveous fat tolerance in man. Atheroscler. 19: 337-346.
PARDRIGE, W.H. 1981. Transport of protein bound hormones into tissues in vivo. Endrocr. Rev. 2:103- 123.
PARROIT, A.C.; CHOI, P.Y.; DAVIES, M. 1994. Anabolic .steroid use by amateur athletes: effects upon psychological mood states. J. Sports Med. Phys. Fitness. 34:292-298.
PERRY, P.J.; MacINDOE, J.; HOLMAN, T.; ELLINGROD, V. 1999. Psychosexual effects of three doses of testosterone cycling in normal men. Biol. Psychiatry. 45:254-260.
PHILLIPS, N. 1990. Guía de referencia anabólica. Ed. Mile High Publ., California. p.90-97.
POPE, H.G. Jr.; KOURI, E.M.; HUDSON, J.I. 2000. Effects of supraphysiologic doses of testosterone on mood and aggression in normalmen: a randomized controlled trial. Arch. Gen. Psychiatry. 57:133-140.
POPE, H.G. Jr.; GRUBER, A.J.; CHOI, P.; OLIVARDIA, R.; PHILLIPS, K.A. 1997. Muscle dysmorphia, an unrecognised form of body dysmorphic disorder. Psychosomatics. 38:548-557.
RIEBE, D.; FERNHALL, B.; THOMPSON, P.D. 1992. The blood pressure response to exercise in anabolic steroid users. Med. Sci. Sports Exerc. 24:633-637.
RODRÍGUEZ BUENO, C. 1992. Dopaje. Ed. McGraw ? Hill, Madrid. p.3-17.
RUEDI, B. 1983. Diagnostic strategy in hyperandrogenic syndrome. Horm. Res. 18:117-124.
SADER, M.A.; GRIFFITHS, K.A.; McCREDIE, R.J.; HANDELSMAN, D.J.; CELERMAJER, D.S. 2001. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J. Am. Coll. Cardiol. 37:224-230.
SADER, M.A.; GRIFFITHS, K.A.; SKILTON, M.R.; WISHART, S.M.; HANDELSMAN, D.J.; CELEMAJER, D.S. 2003. Physiological testosterone replacement and arterial endothelial function in men. Clin. Endocrin. 59:62-67.
SÁEZ DE OCARIZ, M.M. 1997. Esteroides tópicos. Dermatol. Rev. Mex. 41:184-189.
SHEFFIELD-MOORE, M.; URBAN, R.J.; WOLF, S.E.; JIANG, J.; CATLIN, D.H.; HERNDON, D.N.; WOLFE, R.R. 1999. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J. Clin. Endocrin. Metab.; 84(8):2705?2711.
SHIMIZU, K. 1988. Synthesis of deuterium-labeled 17- hydroxi-progesterone suitable as an internal standard for isotope dilution mass spectrometry. Steroids. 51:283-297.
STRAUS, R.H.; LIGGETT, M.; LANESE, R.R. 1985. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA. 253.:2871- 2873.
STURMI, J.E.; DIORIO, D.J. 1998. Anabolic agents. Clin Sports Med. 17:261-282.
SULLIVAN, M.L.; MARTÍNEZ, C.M.; GENNIS, P.; GALLAGHER, E.J. 1998. The cardiac toxicity of anabolic steroids. Prog Cardiovasc. Dis. 41:1-15.
TAUBER, U. 1994. Pharmacokinetics and "bioactivation" of MPA. J. Eur. Acad. Dermatol. Venereol. 3(suppl):S23-31.
TOPERT, M. 1988. Perspectives in corticosteroid research. Drugs. 36(suppl 5):38-42.
TRICKER, R.; CASABURI, R.; STORER, T.W.; CLEVENGER, B.; BERMAN, N.; SHIRAZI, A.; BHASIN, S. 1996. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men-a clinical research center study. J. Clin. Endocr. Metab. 81:3754-3758.
TUREK, P.J.; WILLIAMS, R.H., GILBAUCH, J.H. 3rd; LIPSHULTZ, L.I. 1995. The reversibility. of anabolic steroid-induced azospermia. J. Urol. 153:1628- 1630.
WILSON, J.D. 1988. Androgen abusy by athletes. Endocr. Rev. 9:189-199.
WORLD ANTI?DOPING AGENCY WADA. 2009. World Antidoping Code, Quebec. p.5-10.
YESALIS, C.E.; COWART, V.S. 1999. Esteroides, un juego peligroso. Ed. Hispano Europea. Barcelona. 199p.
YESALIS, C.E.; BAHRKE, M.S. 1995. Anabolicandrogenic steroids. Current issues. Sports Med. 19(5):326-340.
ZITZMANN, M.; BRUNE, M.; NIESCHLAG, E. 2002. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J. Clin. Endocr. Metab. 87:5030?5037.
Citado por
